Yamo Pharmaceuticals plans Phase 3 study for ASD drug in US
1 report, 1 independent
Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Yamo Pharmaceuticals announced plans for a Phase 3 study in the United States for its investigational drug L1-79, which targets core symptoms of autism spectrum disorder. The company noted that its registration site has received over 6,000 inquiries from families in more than 90 countries. The study is planned to open at clinical sites in the United States in early 2027.
From newswise.com
Why it matters
The planned study moves the drug L1-79 closer to potential market availability. Successful completion of the Phase 3 trial, which is regulated by the FDA, could lead to future sales and revenue for Yamo Pharmaceuticals.
From newswise.com
Who's involved
- FDARegulatory agency overseeing the drug development
- United States of AmericaLocation where the Phase 3 clinical sites are planned
Keep exploring
The entities involved
Related events
- TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.